Interviews

Kalveer Flora, MPharm, London North West University Healthcare National Health Service Trust, discusses how patients have reacted to being switched to biosimilar adalimumab and how they have been supported in the switching process.

Julie Maréchal-Jamil, director of biosimilars policy and science at Medicines for Europe, describes the challenges ahead for the European biosimilars market.

Ali McBride, PharmD, MS, BCPS, clinical coordinator of hematology/oncology at the University of Arizona Cancer Center, discusses pharmacists' educational needs on biosimilars.

Kashyap Patel, MD, discusses the goals of the Community Oncology Alliance (COA) in forming its biosimilars committee.

Gary Lyman, MD, MPH, of the Fred Hutchinson Cancer Research Center and Seattle Cancer Care Alliance, describes challenges with incorporating biosimilars into cancer care.

Kashyap Patel, MD, discusses considerations for using biosimilar versus subcutaneous rituximab.

Lee Schwartzberg, MD, FACP, The West Clinic, explains the kinds of education that oncology providers still need to feel comfortable with biosimilars.

Kalveer Flora, MPharm, London North West University Healthcare National Health Service Trust, discusses her trust's extensive experience with switching patients to biosimilars.

Peter Jørgensen, director of the Industrial Association for Generic and Biosimilar Medicines, Denmark, explains the Danish experience with biosimilar adalimumab.

Gary Lyman, MD, MPH, of the Fred Hutchinson Cancer Research Center and Seattle Cancer Care Alliance, discusses how biosimilars could impact the cost of care.

Julie Maréchal-Jamil, director of biosimilars policy and science at Medicines for Europe, describes opportunities for biosimilars in the year ahead.

Kashyap Patel, MD, explains the role that nurses play in educating patients about biosimilars.

James Shehan, JD, chair of regulatory practice at Lowenstein Sandler, LLP, discusses the implications of recent FDA guidance on medical product communications.

Gary Lyman, MD, MPH, of the Fred Hutchinson Cancer Research Center and Seattle Cancer Care Alliance, discusses the role of the first FDA-approved biosimilar epoetin alfa in cancer care.

Lee Schwartzberg, MD, FACP, medical director and senior partner at The West Clinic, explains what he sees as the main challenges with incorporating biosimilars in the cancer clinic.

Suzette Kox, MPharm, Secretary General of the International Generic and Biosimilar Medicines Association (IGBA), discusses challenges faced jointly by the US and EU biosimilars markets.

Julie Maréchal-Jamil, director of biosimilars policy and science at Medicines for Europe, describes current educational needs around biosimilars.

Gary Lyman, MD, MPH, of the Fred Hutchinson Cancer Research Center and Seattle Cancer Care Alliance, describes the biosimilar approval pathway in the United States.

Ali McBride, PharmD, MS, BCPS, clinical coordinator of hematology/oncology at the University of Arizona Cancer Center, discusses experience with biosimilar pegfilgrastim so far.

Lee Schwartzberg, MD, FACP, medical director and senior partner at The West Clinic, discusses his research that showed that the incidence of febrile neutropenia was similar between patients who received reference filgrastim versus those who received a biosimilar.

Suzette Kox, MPharm, Secretary General of the International Generic and Biosimilar Medicines Association (IGBA), discusses the European experience with using nonproprietary names for biosimilar pharmacovigilance.

Anton Franken, MD, PhD, endocrinologist, discusses how to communicate with patients who are going to be switched to biosimilar insulin.

Tahir Amin, DipLP, cofounder and director of intellectual property of Initiative for Medicines, Access, and Knowledge (I-MAK), explains how a recent trade deal could take a toll on biosimilars.

James Shehan, JD, chair of regulatory practice at Lowenstein Sandler, LLP, discusses how the FDA plans to address citizen petitions that impede market entry of competitive products.

Suzette Kox, MPharm, Secretary General of the International Generic and Biosimilar Medicines Association (IGBA), discusses the FDA’s recent guidance on the naming of biosimilars, biologics, and interchangeable products.

Ali McBride, PharmD, MS, BCPS, clinical coordinator of hematology/oncology at the University of Arizona Cancer Center, describes imporant considerations in preparing for the arrival of biosimilar rituximab.

Julie Maréchal-Jamil, director of biosimilars policy and science at Medicines for Europe, describes early experience with biosimilar adalimumab in Europe.

Beata Ambroziewicz, president of the Polish Union of Patient Organizations and board member of the Polish Cancer Patient Coalition, discusses patients' concerns about biosimilars and the need for more education about switching.

Anton Franken, MD, PhD, endocrinologist, discusses how closely patients who switch to biosimilars must be monitored.

Carol Lynch, president of Sandoz US and head of North America, discusses the FDA's role in instilling confidence in biosimilars.